+ Technology/Innovation
Jamie Barrand | Nov 12, 2015

Phase II clinical study of Anifrolumab shows positive lupus treatment results

The Lupus Foundation of America said Tuesday that a discussion of the positive results of a recent Phase II clinical study of Anifrolumab, a potential treatment for systemic lupus, is available on its website.

Anifrolumab is an antibody that fights against the Type I interferon (IFN) receptor that inhibits the activity of all Type I IFNs, from which lupus often originates.

In the study, Anifrolumab produced positive results in 34.4 percent of the patients who were administered 300-milligram doses and in 28.8 percent of the patients who received 1,000-milligram doses.

Dr. Richard Alan Furie, chief of the Division of Rheumatology at North Shore-LIJ Health System, discusses the results in the podcast.

Data gleaned from the study was presented Monday during the American College of Rheumatology's annual scientific meeting in San Francisco. 

Organizations in this story

More News